Inside Precision Medicine June 24, 2024
Access to Helix’s large-scale real-world data and genomics, will help Recursion create and train AI models to develop precision medicines
Helix is providing Recursion Pharmaceuticals access to its vast clinico-genomic data to drive drug discovery innovation. Recursion will use de-identified data from Helix’s extensive network of health systems, such as comprehensive longitudinal clinical records combined with genomic data, to address multiple germline therapeutic areas. Using this data, Recursion intends to train AI models to accelerate drug discovery, develop biomarkers, and improve patient stratification strategies across a range of disease states. The partnership emphasizes combining real-world data and genomics to improve precision medicine development’s speed, efficacy, and scale.
“Multimodal data, including Recursion’s proprietary chemical and biological data combined with Helix’s diverse...
Today's Sponsors
Today's Sponsor